JP2017507151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507151A5 JP2017507151A5 JP2016555458A JP2016555458A JP2017507151A5 JP 2017507151 A5 JP2017507151 A5 JP 2017507151A5 JP 2016555458 A JP2016555458 A JP 2016555458A JP 2016555458 A JP2016555458 A JP 2016555458A JP 2017507151 A5 JP2017507151 A5 JP 2017507151A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- cancer
- eribulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947398P | 2014-03-03 | 2014-03-03 | |
| US61/947,398 | 2014-03-03 | ||
| PCT/US2015/018335 WO2015134399A1 (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507151A JP2017507151A (ja) | 2017-03-16 |
| JP2017507151A5 true JP2017507151A5 (enExample) | 2018-08-30 |
Family
ID=54055761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555458A Pending JP2017507151A (ja) | 2014-03-03 | 2015-03-02 | がんの治療のための併用療法としてのエリブリン及びｍＴＯＲ阻害剤の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170071903A1 (enExample) |
| EP (1) | EP3113775A4 (enExample) |
| JP (1) | JP2017507151A (enExample) |
| KR (1) | KR20160135230A (enExample) |
| CN (1) | CN106029070A (enExample) |
| AU (1) | AU2015225436A1 (enExample) |
| CA (1) | CA2940983A1 (enExample) |
| IL (1) | IL247586A0 (enExample) |
| RU (1) | RU2016136504A (enExample) |
| SG (1) | SG11201607298QA (enExample) |
| WO (1) | WO2015134399A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899026B (zh) | 2004-06-03 | 2016-08-03 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| SI2415470T1 (sl) | 2009-03-30 | 2016-12-30 | Eisai R&D Management Co., Ltd. | Liposomski sestavek |
| ES2705698T3 (es) | 2013-06-26 | 2019-03-26 | Eisai R&D Man Co Ltd | Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124252A2 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| AU2010286334B2 (en) * | 2009-08-27 | 2016-02-04 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| KR20140148412A (ko) * | 2012-04-02 | 2014-12-31 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적인 항-igf-1r 및 항-erbb3 항체의 용량 및 투여 |
-
2015
- 2015-03-02 SG SG11201607298QA patent/SG11201607298QA/en unknown
- 2015-03-02 US US15/123,476 patent/US20170071903A1/en not_active Abandoned
- 2015-03-02 AU AU2015225436A patent/AU2015225436A1/en not_active Abandoned
- 2015-03-02 JP JP2016555458A patent/JP2017507151A/ja active Pending
- 2015-03-02 EP EP15758504.3A patent/EP3113775A4/en not_active Withdrawn
- 2015-03-02 WO PCT/US2015/018335 patent/WO2015134399A1/en not_active Ceased
- 2015-03-02 RU RU2016136504A patent/RU2016136504A/ru unknown
- 2015-03-02 CN CN201580011593.4A patent/CN106029070A/zh active Pending
- 2015-03-02 CA CA2940983A patent/CA2940983A1/en not_active Abandoned
- 2015-03-02 KR KR1020167027369A patent/KR20160135230A/ko not_active Withdrawn
-
2016
- 2016-08-31 IL IL247586A patent/IL247586A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507151A5 (enExample) | ||
| RU2016136504A (ru) | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ | |
| US20170157134A1 (en) | Combination therapy | |
| Wu et al. | Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer | |
| JP2016528162A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| TR201806642T4 (tr) | Kanser tedavileri. | |
| JP2017516802A5 (enExample) | ||
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| JP7530116B2 (ja) | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| JP2021505669A5 (enExample) | ||
| CN107708700A (zh) | 用于治疗癌症的方法 | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| JP7468829B2 (ja) | 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤 | |
| CN101167741B (zh) | 莱菔硫烷和铂类药的抗癌联合制剂 | |
| US20190015421A1 (en) | Biomarkers for Treating Cancer with Apilimod | |
| RU2657604C2 (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| CA2868024A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| Parsyan et al. | Translation initiation in colorectal cancer | |
| US10159659B2 (en) | Predicting response to cancer therapy | |
| CN104606189B (zh) | 一种化合物在制备mTOR抑制剂中的应用 | |
| CA3135916A1 (en) | Combined use of a-nor-5a androstane compound drug and anticancer drug | |
| CN111759844A (zh) | staurosporine在制备治疗胃癌以及胃癌转移的药物中的用途 | |
| Lixia et al. | Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer |